Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Механизмы взаимосвязи атеросклероза и рака предстательной железы: обзор литературы - Научно-практический журнал Cardioсоматика Том 14, №1 (2023)
Механизмы взаимосвязи атеросклероза и рака предстательной железы: обзор литературы
Помешкина С.А., Барбараш О.Л., Помешкин Е.В., Брагин-Мальцев А.И. Механизмы взаимосвязи атеросклероза и рака предстательной железы: обзор литературы. CardioСоматика. 2023. Т. 14, № 1. С. 49-58. DOI: https://doi.org/10.17816/CS195493
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Сердечно-сосудистые заболевания и рак остаются основными причинами госпитализации и смертности во всём мире. Рак предстательной железы (РПЖ) является одним из наиболее распространённых злокачественных заболеваний у мужчин. Появляется всё больше результатов эпидемиологических исследований, показывающих, что большинство пациентов с РПЖ умирают не от рака, а от сердечно-сосудистых заболеваний, в частности от ишемической болезни сердца. За последние годы в ряде исследований, посвящённых взаимосвязи атеросклероза и РПЖ, определили более тесную связь между этими хроническими заболеваниями, чем считалось ранее. Процессы, характерные для развития и прогрессирования обоих заболеваний, включают нарушение регуляции клеточной пролиферации, окислительный стресс, генетические изменения и воспаление. Несмотря на противоречивые данные о роли повышенного уровня холестерина в развитии РПЖ, в течение последнего десятилетия всё больше новых исследований подтвердили его важное значение в развитии и прогрессировании РПЖ, в то время как статины продемонстрировали своё значение в снижении риска развития и прогрессирования заболевания. Представленные данные подтверждают необходимость проведения тщательной оценки сердечно-сосудистых факторов риска, наличия сопутствующих сердечно-сосудистых заболеваний у пациентов с РПЖ с целью применения методов профилактики и лечения заболеваний, связанных с атеросклерозом, для снижения сердечно-сосудистого риска и уменьшения прогрессирования РПЖ.
Ключевые слова: сердечно-сосудистые заболевания; ишемическая болезнь сердца; атеросклероз; рак предстательной железы
Keywords: atherosclerosis; cardiovascular disease; coronary heart disease; prostate cancer
Ключевые слова: сердечно-сосудистые заболевания; ишемическая болезнь сердца; атеросклероз; рак предстательной железы
________________________________________________
Keywords: atherosclerosis; cardiovascular disease; coronary heart disease; prostate cancer
Полный текст
Список литературы
1. Writing Group Members; Mozaffarian D., Benjamin E.J., et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association // Circulation. 2016. Vol. 133, N 4. P. e38–360. doi: 10.1161/CIR.0000000000000350
2. Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 // J Am Coll Cardiol. 2017. Vol. 70, N 1. P. 1–25. doi: 10.1016/j.jacc.2017.04.052
3. Khan M.A., Hashim M.J., Mustafa H., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study // Cureus. 2020. Vol. 12, N 7. P. e9349. doi: 10.7759/cureus.9349
4. Yusuf S., Rangarajan S., Teo K., et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries // N Engl J Med. 2014. Vol. 371, N 9. P. 818–827. doi: 10.1056/NEJMoa1311890
5. Tapia-Vieyra J.V., Delgado-Coello B., Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications // Arch Med Res. 2017. Vol. 48, N 1. P. 12–26. doi: 10.1016/j.arcmed.2017.03.005
6. Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209–249. doi: 10.3322/caac.21660
7. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
8. Thomas J.A. 2nd, Gerber L., Bañez L.L., et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21, N 4. P. 576–581. doi: 10.1158/1055-9965.EPI-11-1017
9. Davis M.K., Rajala J.L., Tyldesley S., et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada // J Oncol. 2015. N 2015. P. 820403. doi: 10.1155/2015/820403
10. Matthes K.L., Pestoni G., Korol D., et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study // Urol Oncol. 2018. Vol. 36, N 6. P. 309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016
11. Zaorsky N.G., Churilla T.M., Egleston B.L., et al. Causes of death among cancer patients // Ann Oncol. 2017. Vol. 28, N 2. P. 400–407. doi: 10.1093/annonc/mdw604
12. Shin D.W., Ahn E., Kim H., et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study // Cancer Causes Control. 2010. Vol. 21, N 6. P. 919–929. doi: 10.1007/s10552-010-9521-x
13. Bhatia N., Santos M., Jones L.W., et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer // Circulation. 2016. Vol. 133, N 5. P. 537–541. doi: 10.1161/CIRCULATIONAHA.115.012519
14. Wallis C.J., Mahar A.L., Satkunasivam R., et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation // Urology. 2016. N 97. P. 145–152. doi: 10.1016/j.urology.2016.08.002
15. Abdollah F., Sammon J.D., Reznor G., et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years // Eur J Surg Oncol. 2015. Vol. 41, N 11. P. 1529–1539. doi: 10.1016/j.ejso.2015.06.011
16. Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity // Nat Rev Immunol. 2015. Vol. 15, N 2. P. 104–116. doi: 10.1038/nri3793
17. Sarrazy V., Sore S., Viaud M., et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation // Cell Rep. 2015. Vol. 13, N 1. P. 132–144. doi: 10.1016/j.celrep.2015.08.068
18. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems // Biochim Biophys Acta. 2013. Vol. 1831, N 6. P. 1124–1133. doi: 10.1016/j.bbalip.2013.03.007
19. Ross S., Stagliano N.E., Donovan M.J., et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression // Ann N Y Acad Sci. 2001. N 947. P. 271–292. Discussion 292–293.
20. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy // N Engl J Med. 2013. Vol. 368, N 21. P. 2004–2013. doi: 10.1056/NEJMra1216063
21. Yadav L., Puri N., Rastogi V., et al. Tumour angiogenesis and angiogenic inhibitors: a review // J Clin Diagn Res. 2015. Vol. 9, N 6. P. XE01–XE05. doi: 10.7860/JCDR/2015/12016.6135
22. Virmani R., Kolodgie F.E., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage // Arterioscler Thromb Vasc Biol. 2005. Vol. 25, N 10. P. 2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18
23. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease // Ther Adv Chronic Dis. 2014. Vol. 5, N 4. P. 178–187. doi: 10.1177/2040622314529325
24. Sosa V., Moliné T., Somoza R., et al. Oxidative stress and cancer: An Overview // Ageing Res Rev. 2013. Vol. 12, N 1. P. 376–390. doi: 10.1016/j.arr.2012.10.004
25. Dixon S., Stockwell B.R. The role of iron and reactive oxygen species in cell death // Nat Chem Biol. 2014. Vol. 10, N 1. P. 9–17. doi: 10.1038/nchembio.1416
26. de Nigris F., Sica V., Herrmann J., et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease // Cell Cycle. 2003. Vol. 2, N 4. P. 325–328.
27. Zhivotovsky B., Orrenius S. Cell cycle and cell death in disease: past, present and future // J Intern Med. 2010. Vol. 268, N 5. P. 395–409. doi: 10.1111/j.1365-2796.2010.02282.x
28. Thompson M.M., Garland C., Barrett-Connor E., et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community // Am J Epidemiol. 1989. Vol. 129, N 3. P. 511–517. doi: 10.1093/oxfordjournals.aje.a115162
29. Asia Pacific Cohort Studies Collaboration; Huxley R., Ansary-Mohaddam A., et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region // Asian Pac J Cancer Prev. 2007. Vol. 8, N 2. P. 199–205.
30. Kitahara C.M., Berrington de Gonzalez A., Freedman N.D., et al. Total cholesterol and cancer risk in a large prospective study in Korea // J Clin Oncol. 2011. Vol. 29, N 12. P. 1592–1598. doi: 10.1200/JCO.2010.31.5200
31. Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era // Int J Cancer. 2008. Vol. 123, N 7. P. 1693–1698. doi: 10.1002/ijc.23715
32. Mondul A.M., Clipp S.L., Helzlsouer K.J., Platz E.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort // Cancer Causes Control. 2010. Vol. 21, N 1. P. 61–68. doi: 10.1007/s10552-009-9434-8
33. Van Hemelrijck M., Garmo H., Holmberg L., et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose // Cancer. 2011. Vol. 117, N 10. P. 2086–2095. doi: 10.1002/cncr.25758
34. Van Hemelrijck M., Walldius G., Jungner I., et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study // Cancer Causes Control. 2011. Vol. 22, N 7. P. 1011–1019. doi: 10.1007/s10552-011-9774-z
35. Farwell W.R., D’Avolio L.W., Scranton R.E., et al. Statins and prostate cancer diagnosis and grade in a veterans population // J Natl Cancer Inst. 2011. Vol. 103, N 11. P. 885–892. doi: 10.1093/jnci/djr108
36. Shafique K., McLoone P., Qureshi K., et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up // BMC Cancer. 2012. N 12. P. 25. doi: 10.1186/1471-2407-12-25
37. Batty G.D., Kivimaki M., Clarke R., et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study // Cancer Causes Control. 2011. Vol. 22, N 2. P. 311–318. doi: 10.1007/s10552-010-9691-6
38. Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes // Annu Rev Biophys Biomol Struct. 2004. N 33. P. 269–295. doi: 10.1146/annurev.biophys.32.110601.141803
39. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis // Reumatol Clin. 2009. Vol. 5, Suppl. 1. P. 40–43. doi: 10.1016/j.reuma.2008.12.008
40. Galbraith L., Leung H.Y., Ahmad I. Lipid pathway deregulation in advanced prostate cancer // Pharmacol Res. 2018. N 131. P. 177–184. doi: 10.1016/j.phrs.2018.02.022
41. Tosi M.R., Bottura G., Lucchi P., et al. Cholesteryl esters in human malignant neoplasms // Int J Mol Med. 2003. Vol. 11, N 1. P. 95–98. doi: 10.3892/ijmm.11.1.95
42. Cheng C., Geng F., Cheng X., Guo D. Lipid metabolism reprogramming and its potential targets in cancer // Cancer Commun (Lond). 2018. Vol. 38, N 1. P. 27.
doi: 10.1186/s40880-018-0301-4
43. Pelton K., Freeman M.R., Solomon K.R. Cholesterol and Prostate Cancer // Curr Opin Pharmacol. 2012. Vol. 12, N 6. P. 751–759. doi: 10.1016/j.coph.2012.07.006
44. Aggarwal B.B., Shishodia S., Sandur S.K., et al. Inflammation and cancer: how hot is the link? // Biochem Pharmacol. 2006. Vol. 72, N 11. P. 1605–1621. doi: 10.1016/j.bcp.2006.06.029
45. Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence // Eur Urol. 2013. Vol. 63, N 5. P. 800–809. doi: 10.1016/j.eururo.2012.11.013
46. Hager M., Mikuz G., Bartsch G., et al. The association between local atherosclerosis and prostate cancer // BJU Int. 2007. Vol. 99, N 1. P. 46–48.
doi: 10.1111/j.1464-410X.2006.06549.x
47. Zhang X., Li G., Hu L., et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy // Med Oncol. 2014. Vol. 31, N 12. P. 297. doi: 10.1007/s12032-014-0297-9
48. Di Francesco S., Robuffo I., Caruso M., et al. Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship // Medicina (Kaunas). 2019. Vol. 55, N 3. P. 62. doi: 10.3390/medicina55030062
49. Cuaron J., Pei X., Cohen G.N., et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer // Brachytherapy. 2015. Vol. 14, N 2. P. 179–184. doi: 10.1016/j.brachy.2014.05.019
50. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis // JAMA. 2006. Vol. 295, N 1. P. 74–80. doi: 10.1001/jama.295.1.74
51. Lustman A., Nakar S., Cohen A.D., Vinker S. Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study // Prostate Cancer Prostatic Dis. 2014. Vol. 17, N 1. P. 6–9. doi: 10.1038/pcan.2013.34
52. Tan P., Wei S., Yang L., et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis // Sci Rep. 2016;6:29106. doi: 10.1038/srep29106
53. Van Rompay M.I., Solomon K.R., Nickel J.C., et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications // Eur J Cancer. 2019. N 112. P. 118–126. doi: 10.1016/j.ejca.2018.11.033
54. Chen J., Zhang B., Chen D., Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: a systematic review and meta-analysis of cohort studies // Int J Clin Exp Med. 2018. Vol. 11, N 9. P. 8873–8885.
55. Flick E.D., Habel L.A., Chan K.A., et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort // Cancer Epidemiol Biomarkers Prev. 2007. Vol. 16, N 11. P. 2218–2225. doi: 10.1158/1055-9965.EPI-07-0197
2. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052
3. Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. doi: 10.7759/cureus.9349
4. Yusuf S, Rangarajan S, Teo K, et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–827. doi: 10.1056/NEJMoa1311890
5. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications. Arch Med Res. 2017;48(1):12–26. doi: 10.1016/j.arcmed.2017.03.005
6. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
7. Kaprin AD, Starinskii VV, Petrova GV, editors. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ).
8. Thomas JA 2nd, Gerber L, Bañez LL, et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012;21(4):576–581. doi: 10.1158/1055-9965.EPI-11-1017
9. Davis MK, Rajala JL, Tyldesley S, et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol. 2015;2015:820403. doi: 10.1155/2015/820403
10. Matthes KL, Pestoni G, Korol D, et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study. Urol Oncol. 2018;36(6):309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016
11. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407. doi: 10.1093/annonc/mdw604
12. Shin DW, Ahn E, Kim H, et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control. 2010;21(6):919–929. doi: 10.1007/s10552-010-9521-x
13. Bhatia N, Santos M, Jones LW, et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016;133(5):537–541. doi: 10.1161/CIRCULATIONAHA.115.012519
14. Wallis CJ, Mahar AL, Satkunasivam R, et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. Urology. 2016;97:145–152. doi: 10.1016/j.urology.2016.08.002
15. Abdollah F, Sammon JD, Reznor G, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. Eur J Surg Oncol. 2015;41(11):1529–1539. doi: 10.1016/j.ejso.2015.06.011
16. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116. doi: 10.1038/nri3793
17. Sarrazy V, Sore S, Viaud M, et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation. Cell Rep. 2015;13(1):132–144. doi: 10.1016/j.celrep.2015.08.068
18. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems. Biochim Biophys Acta. 2013;1831(6):1124–1133. doi: 10.1016/j.bbalip.2013.03.007
19. Ross S, Stagliano NE, Donovan MJ, et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression. Ann N Y Acad Sci. 2001;947:271–292;discussion 292–293.
20. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–2013. doi: 10.1056/NEJMra1216063
21. Yadav L, Puri N, Rastogi V, et al. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res. 2015;9(6):XE01–XE05. doi: 10.7860/JCDR/2015/12016.6135
22. Virmani R, Kolodgie FE, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18
23. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis. 2014;5(4):178–187. doi: 10.1177/2040622314529325
24. Sosa V, Moliné T, Somoza R, et al. Oxidative stress and cancer: An Overview. Ageing Res Rev. 2013;12(1):376–390. doi: 10.1016/j.arr.2012.10.004
25. Dixon S, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9–17. doi: 10.1038/nchembio.1416
26. de Nigris F, Sica V, Herrmann J, et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease. Cell Cycle. 2003;2(4):325–328.
27. Zhivotovsky B, Orrenius S. Cell cycle and cell death in disease: past, present and future. J Intern Med. 2010;268(5):395–409. doi: 10.1111/j.1365-2796.2010.02282.x
28. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989;129(3):511–517. doi: 10.1093/oxfordjournals.aje.a115162
29. Asia Pacific Cohort Studies Collaboration; Huxley R, Ansary-Mohaddam A, et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):199–205.
30. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–1598. doi: 10.1200/JCO.2010.31.5200
31. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008;123(7):1693–1698. doi: 10.1002/ijc.23715
32. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21(1):61–68. doi: 10.1007/s10552-009-9434-8
33. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117(10):2086–2095. doi: 10.1002/cncr.25758
34. Van Hemelrijck M, Walldius G, Jungner I, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22(7):1011–1019. doi: 10.1007/s10552-011-9774-z
35. Farwell WR, D’Avolio LW, Scranton RE, et al. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885–892. doi: 10.1093/jnci/djr108
36. Shafique K, McLoone P, Qureshi K, et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer. 2012;12:25. doi: 10.1186/1471-2407-12-25
37. Batty GD, Kivimaki M, Clarke R, et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311–318. doi: 10.1007/s10552-010-9691-6
38. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct. 2004;33:269–295. doi: 10.1146/annurev.biophys.32.110601.141803
39. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol Clin. 2009;5(Suppl 1):40–43. doi: 10.1016/j.reuma.2008.12.008
40. Galbraith L, Leung HY, Ahmad I. Lipid pathway deregulation in advanced prostate cancer. Pharmacol Res. 2018;131:177–184. doi: 10.1016/j.phrs.2018.02.022
41. Tosi MR, Bottura G, Lucchi P, et al. Cholesteryl esters in human malignant neoplasms. Int J Mol Med. 2003;11(1):95–98. doi: 10.3892/ijmm.11.1.95
42. Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27. doi: 10.1186/s40880-018-0301-4
43. Pelton K, Freeman MR, Solomon KR. Cholesterol and Prostate Cancer. Curr Opin Pharmacol. 2012;12(6):751–759. doi: 10.1016/j.coph.2012.07.006
44. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–1621. doi: 10.1016/j.bcp.2006.06.029
45. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–809. doi: 10.1016/j.eururo.2012.11.013
46. Hager M, Mikuz G, Bartsch G, et al. The association between local atherosclerosis and prostate cancer. BJU Int. 2007;99(1):46–48. doi: 10.1111/j.1464-410X.2006.06549.x
47. Zhang X, Li G, Hu L, et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Med Oncol. 2014;31(12):297. doi: 10.1007/s12032-014-0297-9
48. Di Francesco S, Robuffo I, Caruso M, et al. Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship. Medicina (Kaunas). 2019;55(3):62. doi: 10.3390/medicina55030062
49. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy. 2015;14(2):179–184. doi: 10.1016/j.brachy.2014.05.019
50. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80. doi: 10.1001/jama.295.1.74
51. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis. 2014;17(1):6–9. doi: 10.1038/pcan.2013.34
52. Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6:29106. doi: 10.1038/srep29106
53. Van Rompay MI, Solomon KR, Nickel JC, et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118–126. doi: 10.1016/j.ejca.2018.11.033
54. Chen J, Zhang B, Chen D, Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: a systematic review and meta-analysis of cohort studies. Int J Clin Exp Med. 2018;11(9):8873–8885.
55. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2218–2225. doi: 10.1158/1055-9965.EPI-07-0197
2. Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 // J Am Coll Cardiol. 2017. Vol. 70, N 1. P. 1–25. doi: 10.1016/j.jacc.2017.04.052
3. Khan M.A., Hashim M.J., Mustafa H., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study // Cureus. 2020. Vol. 12, N 7. P. e9349. doi: 10.7759/cureus.9349
4. Yusuf S., Rangarajan S., Teo K., et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries // N Engl J Med. 2014. Vol. 371, N 9. P. 818–827. doi: 10.1056/NEJMoa1311890
5. Tapia-Vieyra J.V., Delgado-Coello B., Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications // Arch Med Res. 2017. Vol. 48, N 1. P. 12–26. doi: 10.1016/j.arcmed.2017.03.005
6. Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209–249. doi: 10.3322/caac.21660
7. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
8. Thomas J.A. 2nd, Gerber L., Bañez L.L., et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21, N 4. P. 576–581. doi: 10.1158/1055-9965.EPI-11-1017
9. Davis M.K., Rajala J.L., Tyldesley S., et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada // J Oncol. 2015. N 2015. P. 820403. doi: 10.1155/2015/820403
10. Matthes K.L., Pestoni G., Korol D., et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study // Urol Oncol. 2018. Vol. 36, N 6. P. 309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016
11. Zaorsky N.G., Churilla T.M., Egleston B.L., et al. Causes of death among cancer patients // Ann Oncol. 2017. Vol. 28, N 2. P. 400–407. doi: 10.1093/annonc/mdw604
12. Shin D.W., Ahn E., Kim H., et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study // Cancer Causes Control. 2010. Vol. 21, N 6. P. 919–929. doi: 10.1007/s10552-010-9521-x
13. Bhatia N., Santos M., Jones L.W., et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer // Circulation. 2016. Vol. 133, N 5. P. 537–541. doi: 10.1161/CIRCULATIONAHA.115.012519
14. Wallis C.J., Mahar A.L., Satkunasivam R., et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation // Urology. 2016. N 97. P. 145–152. doi: 10.1016/j.urology.2016.08.002
15. Abdollah F., Sammon J.D., Reznor G., et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years // Eur J Surg Oncol. 2015. Vol. 41, N 11. P. 1529–1539. doi: 10.1016/j.ejso.2015.06.011
16. Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity // Nat Rev Immunol. 2015. Vol. 15, N 2. P. 104–116. doi: 10.1038/nri3793
17. Sarrazy V., Sore S., Viaud M., et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation // Cell Rep. 2015. Vol. 13, N 1. P. 132–144. doi: 10.1016/j.celrep.2015.08.068
18. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems // Biochim Biophys Acta. 2013. Vol. 1831, N 6. P. 1124–1133. doi: 10.1016/j.bbalip.2013.03.007
19. Ross S., Stagliano N.E., Donovan M.J., et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression // Ann N Y Acad Sci. 2001. N 947. P. 271–292. Discussion 292–293.
20. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy // N Engl J Med. 2013. Vol. 368, N 21. P. 2004–2013. doi: 10.1056/NEJMra1216063
21. Yadav L., Puri N., Rastogi V., et al. Tumour angiogenesis and angiogenic inhibitors: a review // J Clin Diagn Res. 2015. Vol. 9, N 6. P. XE01–XE05. doi: 10.7860/JCDR/2015/12016.6135
22. Virmani R., Kolodgie F.E., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage // Arterioscler Thromb Vasc Biol. 2005. Vol. 25, N 10. P. 2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18
23. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease // Ther Adv Chronic Dis. 2014. Vol. 5, N 4. P. 178–187. doi: 10.1177/2040622314529325
24. Sosa V., Moliné T., Somoza R., et al. Oxidative stress and cancer: An Overview // Ageing Res Rev. 2013. Vol. 12, N 1. P. 376–390. doi: 10.1016/j.arr.2012.10.004
25. Dixon S., Stockwell B.R. The role of iron and reactive oxygen species in cell death // Nat Chem Biol. 2014. Vol. 10, N 1. P. 9–17. doi: 10.1038/nchembio.1416
26. de Nigris F., Sica V., Herrmann J., et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease // Cell Cycle. 2003. Vol. 2, N 4. P. 325–328.
27. Zhivotovsky B., Orrenius S. Cell cycle and cell death in disease: past, present and future // J Intern Med. 2010. Vol. 268, N 5. P. 395–409. doi: 10.1111/j.1365-2796.2010.02282.x
28. Thompson M.M., Garland C., Barrett-Connor E., et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community // Am J Epidemiol. 1989. Vol. 129, N 3. P. 511–517. doi: 10.1093/oxfordjournals.aje.a115162
29. Asia Pacific Cohort Studies Collaboration; Huxley R., Ansary-Mohaddam A., et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region // Asian Pac J Cancer Prev. 2007. Vol. 8, N 2. P. 199–205.
30. Kitahara C.M., Berrington de Gonzalez A., Freedman N.D., et al. Total cholesterol and cancer risk in a large prospective study in Korea // J Clin Oncol. 2011. Vol. 29, N 12. P. 1592–1598. doi: 10.1200/JCO.2010.31.5200
31. Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era // Int J Cancer. 2008. Vol. 123, N 7. P. 1693–1698. doi: 10.1002/ijc.23715
32. Mondul A.M., Clipp S.L., Helzlsouer K.J., Platz E.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort // Cancer Causes Control. 2010. Vol. 21, N 1. P. 61–68. doi: 10.1007/s10552-009-9434-8
33. Van Hemelrijck M., Garmo H., Holmberg L., et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose // Cancer. 2011. Vol. 117, N 10. P. 2086–2095. doi: 10.1002/cncr.25758
34. Van Hemelrijck M., Walldius G., Jungner I., et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study // Cancer Causes Control. 2011. Vol. 22, N 7. P. 1011–1019. doi: 10.1007/s10552-011-9774-z
35. Farwell W.R., D’Avolio L.W., Scranton R.E., et al. Statins and prostate cancer diagnosis and grade in a veterans population // J Natl Cancer Inst. 2011. Vol. 103, N 11. P. 885–892. doi: 10.1093/jnci/djr108
36. Shafique K., McLoone P., Qureshi K., et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up // BMC Cancer. 2012. N 12. P. 25. doi: 10.1186/1471-2407-12-25
37. Batty G.D., Kivimaki M., Clarke R., et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study // Cancer Causes Control. 2011. Vol. 22, N 2. P. 311–318. doi: 10.1007/s10552-010-9691-6
38. Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes // Annu Rev Biophys Biomol Struct. 2004. N 33. P. 269–295. doi: 10.1146/annurev.biophys.32.110601.141803
39. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis // Reumatol Clin. 2009. Vol. 5, Suppl. 1. P. 40–43. doi: 10.1016/j.reuma.2008.12.008
40. Galbraith L., Leung H.Y., Ahmad I. Lipid pathway deregulation in advanced prostate cancer // Pharmacol Res. 2018. N 131. P. 177–184. doi: 10.1016/j.phrs.2018.02.022
41. Tosi M.R., Bottura G., Lucchi P., et al. Cholesteryl esters in human malignant neoplasms // Int J Mol Med. 2003. Vol. 11, N 1. P. 95–98. doi: 10.3892/ijmm.11.1.95
42. Cheng C., Geng F., Cheng X., Guo D. Lipid metabolism reprogramming and its potential targets in cancer // Cancer Commun (Lond). 2018. Vol. 38, N 1. P. 27.
doi: 10.1186/s40880-018-0301-4
43. Pelton K., Freeman M.R., Solomon K.R. Cholesterol and Prostate Cancer // Curr Opin Pharmacol. 2012. Vol. 12, N 6. P. 751–759. doi: 10.1016/j.coph.2012.07.006
44. Aggarwal B.B., Shishodia S., Sandur S.K., et al. Inflammation and cancer: how hot is the link? // Biochem Pharmacol. 2006. Vol. 72, N 11. P. 1605–1621. doi: 10.1016/j.bcp.2006.06.029
45. Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence // Eur Urol. 2013. Vol. 63, N 5. P. 800–809. doi: 10.1016/j.eururo.2012.11.013
46. Hager M., Mikuz G., Bartsch G., et al. The association between local atherosclerosis and prostate cancer // BJU Int. 2007. Vol. 99, N 1. P. 46–48.
doi: 10.1111/j.1464-410X.2006.06549.x
47. Zhang X., Li G., Hu L., et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy // Med Oncol. 2014. Vol. 31, N 12. P. 297. doi: 10.1007/s12032-014-0297-9
48. Di Francesco S., Robuffo I., Caruso M., et al. Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship // Medicina (Kaunas). 2019. Vol. 55, N 3. P. 62. doi: 10.3390/medicina55030062
49. Cuaron J., Pei X., Cohen G.N., et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer // Brachytherapy. 2015. Vol. 14, N 2. P. 179–184. doi: 10.1016/j.brachy.2014.05.019
50. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis // JAMA. 2006. Vol. 295, N 1. P. 74–80. doi: 10.1001/jama.295.1.74
51. Lustman A., Nakar S., Cohen A.D., Vinker S. Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study // Prostate Cancer Prostatic Dis. 2014. Vol. 17, N 1. P. 6–9. doi: 10.1038/pcan.2013.34
52. Tan P., Wei S., Yang L., et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis // Sci Rep. 2016;6:29106. doi: 10.1038/srep29106
53. Van Rompay M.I., Solomon K.R., Nickel J.C., et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications // Eur J Cancer. 2019. N 112. P. 118–126. doi: 10.1016/j.ejca.2018.11.033
54. Chen J., Zhang B., Chen D., Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: a systematic review and meta-analysis of cohort studies // Int J Clin Exp Med. 2018. Vol. 11, N 9. P. 8873–8885.
55. Flick E.D., Habel L.A., Chan K.A., et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort // Cancer Epidemiol Biomarkers Prev. 2007. Vol. 16, N 11. P. 2218–2225. doi: 10.1158/1055-9965.EPI-07-0197
________________________________________________
2. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052
3. Khan MA, Hashim MJ, Mustafa H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. doi: 10.7759/cureus.9349
4. Yusuf S, Rangarajan S, Teo K, et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–827. doi: 10.1056/NEJMoa1311890
5. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications. Arch Med Res. 2017;48(1):12–26. doi: 10.1016/j.arcmed.2017.03.005
6. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
7. Kaprin AD, Starinskii VV, Petrova GV, editors. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ).
8. Thomas JA 2nd, Gerber L, Bañez LL, et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012;21(4):576–581. doi: 10.1158/1055-9965.EPI-11-1017
9. Davis MK, Rajala JL, Tyldesley S, et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. J Oncol. 2015;2015:820403. doi: 10.1155/2015/820403
10. Matthes KL, Pestoni G, Korol D, et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study. Urol Oncol. 2018;36(6):309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016
11. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407. doi: 10.1093/annonc/mdw604
12. Shin DW, Ahn E, Kim H, et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control. 2010;21(6):919–929. doi: 10.1007/s10552-010-9521-x
13. Bhatia N, Santos M, Jones LW, et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016;133(5):537–541. doi: 10.1161/CIRCULATIONAHA.115.012519
14. Wallis CJ, Mahar AL, Satkunasivam R, et al. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. Urology. 2016;97:145–152. doi: 10.1016/j.urology.2016.08.002
15. Abdollah F, Sammon JD, Reznor G, et al. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. Eur J Surg Oncol. 2015;41(11):1529–1539. doi: 10.1016/j.ejso.2015.06.011
16. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116. doi: 10.1038/nri3793
17. Sarrazy V, Sore S, Viaud M, et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation. Cell Rep. 2015;13(1):132–144. doi: 10.1016/j.celrep.2015.08.068
18. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems. Biochim Biophys Acta. 2013;1831(6):1124–1133. doi: 10.1016/j.bbalip.2013.03.007
19. Ross S, Stagliano NE, Donovan MJ, et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression. Ann N Y Acad Sci. 2001;947:271–292;discussion 292–293.
20. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–2013. doi: 10.1056/NEJMra1216063
21. Yadav L, Puri N, Rastogi V, et al. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res. 2015;9(6):XE01–XE05. doi: 10.7860/JCDR/2015/12016.6135
22. Virmani R, Kolodgie FE, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18
23. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease. Ther Adv Chronic Dis. 2014;5(4):178–187. doi: 10.1177/2040622314529325
24. Sosa V, Moliné T, Somoza R, et al. Oxidative stress and cancer: An Overview. Ageing Res Rev. 2013;12(1):376–390. doi: 10.1016/j.arr.2012.10.004
25. Dixon S, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9–17. doi: 10.1038/nchembio.1416
26. de Nigris F, Sica V, Herrmann J, et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease. Cell Cycle. 2003;2(4):325–328.
27. Zhivotovsky B, Orrenius S. Cell cycle and cell death in disease: past, present and future. J Intern Med. 2010;268(5):395–409. doi: 10.1111/j.1365-2796.2010.02282.x
28. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol. 1989;129(3):511–517. doi: 10.1093/oxfordjournals.aje.a115162
29. Asia Pacific Cohort Studies Collaboration; Huxley R, Ansary-Mohaddam A, et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007;8(2):199–205.
30. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–1598. doi: 10.1200/JCO.2010.31.5200
31. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008;123(7):1693–1698. doi: 10.1002/ijc.23715
32. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21(1):61–68. doi: 10.1007/s10552-009-9434-8
33. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117(10):2086–2095. doi: 10.1002/cncr.25758
34. Van Hemelrijck M, Walldius G, Jungner I, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22(7):1011–1019. doi: 10.1007/s10552-011-9774-z
35. Farwell WR, D’Avolio LW, Scranton RE, et al. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885–892. doi: 10.1093/jnci/djr108
36. Shafique K, McLoone P, Qureshi K, et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer. 2012;12:25. doi: 10.1186/1471-2407-12-25
37. Batty GD, Kivimaki M, Clarke R, et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311–318. doi: 10.1007/s10552-010-9691-6
38. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct. 2004;33:269–295. doi: 10.1146/annurev.biophys.32.110601.141803
39. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis. Reumatol Clin. 2009;5(Suppl 1):40–43. doi: 10.1016/j.reuma.2008.12.008
40. Galbraith L, Leung HY, Ahmad I. Lipid pathway deregulation in advanced prostate cancer. Pharmacol Res. 2018;131:177–184. doi: 10.1016/j.phrs.2018.02.022
41. Tosi MR, Bottura G, Lucchi P, et al. Cholesteryl esters in human malignant neoplasms. Int J Mol Med. 2003;11(1):95–98. doi: 10.3892/ijmm.11.1.95
42. Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27. doi: 10.1186/s40880-018-0301-4
43. Pelton K, Freeman MR, Solomon KR. Cholesterol and Prostate Cancer. Curr Opin Pharmacol. 2012;12(6):751–759. doi: 10.1016/j.coph.2012.07.006
44. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–1621. doi: 10.1016/j.bcp.2006.06.029
45. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–809. doi: 10.1016/j.eururo.2012.11.013
46. Hager M, Mikuz G, Bartsch G, et al. The association between local atherosclerosis and prostate cancer. BJU Int. 2007;99(1):46–48. doi: 10.1111/j.1464-410X.2006.06549.x
47. Zhang X, Li G, Hu L, et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Med Oncol. 2014;31(12):297. doi: 10.1007/s12032-014-0297-9
48. Di Francesco S, Robuffo I, Caruso M, et al. Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship. Medicina (Kaunas). 2019;55(3):62. doi: 10.3390/medicina55030062
49. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy. 2015;14(2):179–184. doi: 10.1016/j.brachy.2014.05.019
50. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80. doi: 10.1001/jama.295.1.74
51. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis. 2014;17(1):6–9. doi: 10.1038/pcan.2013.34
52. Tan P, Wei S, Yang L, et al. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6:29106. doi: 10.1038/srep29106
53. Van Rompay MI, Solomon KR, Nickel JC, et al. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118–126. doi: 10.1016/j.ejca.2018.11.033
54. Chen J, Zhang B, Chen D, Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: a systematic review and meta-analysis of cohort studies. Int J Clin Exp Med. 2018;11(9):8873–8885.
55. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2218–2225. doi: 10.1158/1055-9965.EPI-07-0197
Авторы
С.А. Помешкина1, О.Л. Барбараш1, Е.В. Помешкин2, А.И. Брагин-Мальцев3
1 НИИ комплексных проблем сердечно-сосудистых заболеваний, Кемерово, Российская Федерация
2 Кемеровский государственный университет, Кемерово, Российская Федерация
3 Кемеровский государственный медицинский университет, Кемерово, Российская Федерация
*swetlana.sap2@mail.ru
1 Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
2 Kemerovo State University, Kemerovo, Russian Federation
3 Kemerovo State Medical University, Kemerovo, Russian Federation
*swetlana.sap2@mail.ru
1 НИИ комплексных проблем сердечно-сосудистых заболеваний, Кемерово, Российская Федерация
2 Кемеровский государственный университет, Кемерово, Российская Федерация
3 Кемеровский государственный медицинский университет, Кемерово, Российская Федерация
*swetlana.sap2@mail.ru
________________________________________________
1 Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
2 Kemerovo State University, Kemerovo, Russian Federation
3 Kemerovo State Medical University, Kemerovo, Russian Federation
*swetlana.sap2@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.